Corporate partnership CR-CP Life Science Fund led the cancer detection test developer’s series C round, which took its total funding to $120m.

Singapore-based cancer diagnostics technology developer Mirxes has secured $77m in a series C round led by CR-CP Life Science Fund, a partnership between conglomerates China Resources Group and Charoen Pokphand Group.

The round also featured Rock Springs Capital, EDBI, CCBI and Keytone Ventures. It took the company’s overall funding to $120m since it was founded in 2014, Mirxes said.

Spun out of Singapore’s public research and development hub Agency for Science, Technology, and Research, Mirxes is developing RNA-based tests designed…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Edison Fu

Edison Fu is a reporter and Asia liaison at Global Corporate Venturing.
Email LinkedIn